Fig. 2From: A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndromeConsort diagram. Disposition of study participants. The intention-to-treat population consisted of all participants who had at least one post-baseline measurement on the primary outcome (CGI-I) and received at least one dose of medication (n = 55)Back to article page